Bcl-3 expression in primary lymphomas on tissue microarrays. Each column represents one single lymphoma case. (A) NK/T-cell–derived lymphomas and borderline cases (n = 52; NK, natural killer cell lymphoma; EATCL, enteropathy-type TCL; AILD, angioimmunoblastic TCL; cTCL, primary cutaneous TCL; pTCL, peripheral TCL unspecified; ALCL, anaplastic large-cell lymphoma; BC, borderline cases between ALK-negative ALCL and cHL), (B) Hodgkin lymphomas (n = 72; LPHL, lymphocyte-predominant Hodgkin lymphoma; cHL, classic HL), and (C, D) other B-cell–derived lymphomas (n = 164; DLBCL, diffuse large B-cell lymphoma; ana, anaplastic variant; ib, immunoblastic variant; cb, centroblastic variant; cbib, centro-/immunoblastic variant; med, primary mediastinal; MCL, mantle-cell lymphoma; FCL, follicular lymphoma; gMALT, gastric marginal zone lymphoma of mucosa-associated lymphoid tissue; Plasm, plasmacytoma) were analyzed for Bcl-3 expression by immunohistochemistry. Staining intensity was: absent, 10; single positive cells, 20; weak, < 50%, 50; weak, 100; intermediate, < 50%, 150; intermediate, 200; strong, < 50%, 250; strong, 300. ^*Copy number increases (3 or more signals) of the BCL3 gene locus, analyzed by FISH.